Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
There is a paucity of data on biopsy-proven kidney disease among people living with Human Immunodeficiency Virus (HIV) in India, where 2.5 million people are living with HIV. People living with HIV have a higher risk of kidney disease than those who are not. This study aimed to characterise the spectrum of biopsy-proven kidney disease among persons living with HIV, and to assess the association between the main histologic outcome and the clinical and demographic features.
We conducted a cross-sectional descriptive and analytical study of 107 native kidney biopsies of people living with HIV reported between January 1st 2023, and July 31st 2025. We retrospectively obtained clinicopathologic data. Descriptive and inferential statistics were applied, with inferential statistics utilised to assess associations between the primary outcome and clinical variables. A P-value of less than 0.05 was considered significant at a 95% CI.
The patients had a mean age of 51 years (±10 years), and 61.7% were male. Seventy-four (69.1%) patients were on antiretroviral therapy (ART), one (0.9%) was not, and 29.9% were of unknown ART status. Median cluster of differentiation (CD4) cell count (n=8) was 498 cells/μl (IQR 222.3-983.5). Median duration of ART (n=36) was 8 years (IQR 4.5-11.0). Most patients were on a Tenofovir-based ART regimen (31/51, 60.8%). Diabetes mellitus was reported in 46.0% (n=65) and hypertension in 61.0% (n=66) of the patients. Acute Kidney Injury was the most common presentation (61/107, 57.0%). Pathology (Figures 1 to 3) showed that tubulointerstitial dominant disease (TID) was the most common (60.7%), and this was associated with increasing age (AOR = 1.06, 95% CI: 1.02–1.12, p = 0.007). The diseases also included glomerular dominant (23.4%), vascular dominant (2.8%), and other diseases (13.1%). Immune complex-mediated diseases were common, including IgA Nephropathy (8.4%), Membranous Nephropathy (MN, 7.5%) and Lupus Nephritis (1.9%). Fifty per cent of MN cases were Phospholipase A2 receptor positive. Diabetic nephropathy accounted for 6.5% of the cases.
The spectrum of kidney disease among people living with HIV was varied. Tubulointerstitial dominant disease was the most common, and it was associated with increasing age. Increased awareness of the spectrum of kidney disease among people living with HIV may lead to improved early diagnosis, treatment, and better outcomes. This work was presented at the Annual Conference of Indian Society of Renal and Transplantation Pathology in Ahmedabad, India ( September 18-20, 2025).
